Canaccord Genuity set a $85.00 price target on Radius Health Inc. (NASDAQ:RDUS) in a report released on Monday. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Radius Health from a hold rating to a sell rating in a report on Monday, August 8th. Jefferies Group reaffirmed a hold rating on shares of Radius Health in a report on Friday, August 5th. HC Wainwright started coverage on Radius Health in a report on Monday, May 23rd. They set a buy rating and a $55.00 target price for the company. Maxim Group lowered Radius Health from a hold rating to a sell rating and set a $24.00 target price for the company. in a report on Thursday, August 4th. Finally, Cowen and Company reaffirmed a buy rating on shares of Radius Health in a report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $63.51.

Radius Health (NASDAQ:RDUS) opened at 56.82 on Monday. The stock has a 50 day moving average price of $54.95 and a 200 day moving average price of $41.07. The firm’s market cap is $2.45 billion. Radius Health has a 1-year low of $24.75 and a 1-year high of $77.10.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.06. During the same period in the prior year, the firm earned ($0.61) earnings per share. On average, analysts anticipate that Radius Health will post ($3.95) EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Radius Health by 27.9% in the second quarter. BlackRock Inc. now owns 2,852 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 623 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of Radius Health by 6.2% in the second quarter. Fifth Third Bancorp now owns 3,421 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 201 shares during the last quarter. Opera Trading Capital bought a new stake in shares of Radius Health during the first quarter valued at $138,000. Teacher Retirement System of Texas increased its stake in shares of Radius Health by 21.4% in the second quarter. Teacher Retirement System of Texas now owns 4,169 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 736 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in shares of Radius Health by 11.7% in the first quarter. Envestnet Asset Management Inc. now owns 5,100 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 535 shares during the last quarter. Hedge funds and other institutional investors own 99.91% of the company’s stock.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.